- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: J wave.
Displaying page 1 of 1.
EudraCT Number: 2007-005103-18 | Sponsor Protocol Number: NC20971 | Start Date*: 2008-03-21 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Synd... | |||||||||||||
Medical condition: Stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) SK (Completed) ES (Prematurely Ended) IE (Prematurely Ended) DK (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003895-65 | Sponsor Protocol Number: DAL-301 | Start Date*: 2016-06-22 | |||||||||||
Sponsor Name:DalCor Pharma UK Ltd, Leatherhead, Swiss Branch Zug | |||||||||||||
Full Title: A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Sy... | |||||||||||||
Medical condition: This study is investigating the cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects wit... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) SE (Completed) SK (Completed) DK (Completed) FI (Completed) PT (Completed) DE (Completed) HU (Completed) ES (Ongoing) AT (Completed) CZ (Completed) BG (Completed) RO (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005462-30 | Sponsor Protocol Number: MDCO-APO-14-01 | Start Date*: 2016-10-26 |
Sponsor Name:The Medicines Company | ||
Full Title: A multiple dose, dose-finding, placebo controlled, double blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and evaluate the effi... | ||
Medical condition: acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-000826-13 | Sponsor Protocol Number: MDCO-APO-15-01 | Start Date*: 2016-01-20 |
Sponsor Name:The Medicines Company | ||
Full Title: A placebo-controlled, double-blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and to evaluate the efficacy, pharmacokinetics, sa... | ||
Medical condition: acute coronary syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Completed) NL (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002892-34 | Sponsor Protocol Number: D3560L00052 | Start Date*: 2005-10-28 |
Sponsor Name:AstraZeneca SAS | ||
Full Title: Comparison of the Effects Noted in The ApoB/ApoA-I ratio Using Rosuvastatin and atorvastatin in patients with acUte coronary Syndrome. | ||
Medical condition: Men or women who are >18 and <75 years old diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS) and onset of clinical symptoms less than 24 hours at the admission for which a PCI is... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) ES (Completed) PT (Completed) EE (Completed) HU (Completed) IT (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003418-25 | Sponsor Protocol Number: CTU/2014/120 | Start Date*: 2016-03-29 | |||||||||||
Sponsor Name:MeiraGTx UK II Ltd | |||||||||||||
Full Title: An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-Associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children with Retinal Dystrophy associated with D... | |||||||||||||
Medical condition: Leber Congenital Amaurosis (LCA) caused by mutations in RPE65 | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004013-25 | Sponsor Protocol Number: IMBE-01/2015 | Start Date*: 2016-09-20 | |||||||||||
Sponsor Name:Institute of Molecular Medicine and Biomedical Research- I.M.B.E. | |||||||||||||
Full Title: Mirabegron in the management of lower urinary tract symptoms (LUTS) related to double-J (JJ) ureteral stents. | |||||||||||||
Medical condition: Insertion of a JJ stent, prior to extracorporal shock wave lithotripsy (ESWL) and post ureterolithotripsy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002942-20 | Sponsor Protocol Number: EFC5826 | Start Date*: 2005-12-29 | |||||||||||
Sponsor Name:sanofi-aventis recherche et developpement | |||||||||||||
Full Title: Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20 mg OD for reducing the risk of major cardiovascular events in abdominally obe... | |||||||||||||
Medical condition: Patients with abdominal obesity at increased risk for cardiovascular events (myocardial infarctio, stroke and cardiovascular death) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prohibited by CA) GB (Prematurely Ended) ES (Completed) DE (Completed) AT (Prematurely Ended) FI (Completed) BE (Completed) DK (Suspended by CA) HU (Completed) CZ (Suspended by CA) IE (Prematurely Ended) PT (Completed) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007093-37 | Sponsor Protocol Number: ACV20616 | Start Date*: 2009-05-27 | |||||||||||
Sponsor Name:Actavis Deutschland GmbH & Co.Kg | |||||||||||||
Full Title: Clinical efficacy of Pentalong® in stable Angina patients after 12 Weeks of routine administration:a randomised, double-blind, placebo-controlled trial. | |||||||||||||
Medical condition: Stable, effort-induced angina pectoris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) ES (Prematurely Ended) IS (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
